Screener
Avalo Therapeutics AVTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's net income?
- Avalo Therapeutics (AVTX) reported net income of -$36.36M in Q2 2026.
- How has Avalo Therapeutics's net income changed year-over-year?
- Avalo Therapeutics's net income decreased by 75.1% year-over-year, from -$20.77M to -$36.36M.
- What is the long-term trend for Avalo Therapeutics's net income?
- Over 4 years (2021 to 2025), Avalo Therapeutics's net income has grown at a -1.9% compound annual growth rate (CAGR), from -$84.38M to -$78.26M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Avalo Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude